Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Sustained elevation of MG53 in the bloodstream increases tissue regenerative capacity without compromising metabolic function.

Bian Z, Wang Q, Zhou X, Tan T, Park KH, Kramer HF, McDougal A, Laping NJ, Kumar S, Adesanya TMA, Sermersheim M, Yi F, Wang X, Wu J, Gumpper K, Jiang Q, He D, Lin PH, Li H, Guan F, Zhou J, Kohr MJ, Zeng C, Zhu H, Ma J.

Nat Commun. 2019 Oct 11;10(1):4659. doi: 10.1038/s41467-019-12483-0.

2.

PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome.

Grande V, Ornaghi F, Comerio L, Restelli E, Masone A, Corbelli A, Tolomeo D, Capone V, Axten JM, Laping NJ, Fiordaliso F, Sallese M, Chiesa R.

Hum Mol Genet. 2018 Jul 15;27(14):2477-2489. doi: 10.1093/hmg/ddy152.

PMID:
29718201
3.

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

Laping NJ, DeMartino MP, Cottom JE, Axten JM, Emery JG, Guss JH, Burman M, Foley JJ, Cheung M, Oliff A, Kumar S.

Blood Adv. 2017 Dec 8;1(26):2553-2562. doi: 10.1182/bloodadvances.2017010611. eCollection 2017 Dec 12.

4.

Effects of Rho-kinase inhibition on myosin light chain phosphorylation and obstruction-induced detrusor overactivity.

Marx JO, Basha ME, Mohanan S, Hypolite JA, Chang S, Wein AJ, Zderic SA, Laping NJ, Chacko S.

Int J Urol. 2014 Mar;21(3):319-24. doi: 10.1111/iju.12247. Epub 2013 Aug 29.

5.

Voltage-gated Na+ channel blockers reduce functional bladder capacity in the conscious spontaneously hypertensive rat.

Clouse AK, Jugus MJ, Eisennagel SH, Laping NJ, Westfall TD, Thorneloe KS.

Urology. 2012 Jun;79(6):1410.e1-6. doi: 10.1016/j.urology.2012.02.016. Epub 2012 Apr 11.

PMID:
22497980
6.

Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.

Dluzen DE, McDermott JL, Bourque M, Di Paolo T, Darvesh AS, Buletko AB, Laping NJ.

Curr Neuropharmacol. 2011 Mar;9(1):40-4. doi: 10.2174/157015911795017399.

7.

Improving the developability profile of pyrrolidine progesterone receptor partial agonists.

Kallander LS, Washburn DG, Hoang TH, Frazee JS, Stoy P, Johnson L, Lu Q, Hammond M, Barton LS, Patterson JR, Azzarano LM, Nagilla R, Madauss KP, Williams SP, Stewart EL, Duraiswami C, Grygielko ET, Xu X, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25.

PMID:
19926282
8.

Estrogen-induced stromal cell-derived factor-1 (SDF-1/Cxcl12) expression is repressed by progesterone and by Selective Estrogen Receptor Modulators via estrogen receptor alpha in rat uterine cells and tissues.

Glace L, Grygielko ET, Boyle R, Wang Q, Laping NJ, Sulpizio AC, Bray JD.

Steroids. 2009 Nov-Dec;74(13-14):1015-24. doi: 10.1016/j.steroids.2009.07.011. Epub 2009 Aug 7.

PMID:
19665469
9.

Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.

Thompson SK, Washburn DG, Frazee JS, Madauss KP, Hoang TH, Lapinski L, Grygielko ET, Glace LE, Trizna W, Williams SP, Duraiswami C, Bray JD, Laping NJ.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4777-80. doi: 10.1016/j.bmcl.2009.06.055. Epub 2009 Jun 17.

PMID:
19595590
10.

Effect of estrogen and progesterone on urodynamics in the conscious rat.

Patra PB, Thorneloe KS, Laping NJ.

Urology. 2009 Aug;74(2):463-6. doi: 10.1016/j.urology.2008.12.046. Epub 2009 Jul 2.

PMID:
19573897
11.

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors.

Hammond M, Washburn DG, Hoang HT, Manns S, Frazee JS, Nakamura H, Patterson JR, Trizna W, Wu C, Azzarano LM, Nagilla R, Nord M, Trejo R, Head MS, Zhao B, Smallwood AM, Hightower K, Laping NJ, Schnackenberg CG, Thompson SK.

Bioorg Med Chem Lett. 2009 Aug 1;19(15):4441-5. doi: 10.1016/j.bmcl.2009.05.051. Epub 2009 May 18.

PMID:
19497745
12.

Dual modulation of urinary bladder activity and urine flow by prostanoid EP3 receptors in the conscious rat.

Jugus MJ, Jaworski JP, Patra PB, Jin J, Morrow DM, Laping NJ, Edwards RM, Thorneloe KS.

Br J Pharmacol. 2009 Sep;158(1):372-81. doi: 10.1111/j.1476-5381.2009.00275.x. Epub 2009 May 22.

13.

Synthesis and SAR of amino acid-derived heterocyclic progesterone receptor full and partial agonists.

Hammond M, Patterson JR, Manns S, Hoang TH, Washburn DG, Trizna W, Glace L, Grygielko ET, Nagilla R, Nord M, Fries HE, Minick DJ, Laping NJ, Bray JD, Thompson SK.

Bioorg Med Chem Lett. 2009 May 15;19(10):2637-41. doi: 10.1016/j.bmcl.2009.03.146. Epub 2009 Apr 5.

PMID:
19376703
14.

Urodynamic measurements by radiotelemetry in conscious, freely moving beagle dogs.

McCafferty GP, Coatney RW, Laping NJ, Thorneloe KS.

J Urol. 2009 Mar;181(3):1444-51. doi: 10.1016/j.juro.2008.10.137. Epub 2009 Jan 20.

PMID:
19157444
15.

Evaluation of pressor and visceromotor reflex responses to bladder distension in urethane anesthetized rats.

Blatt LK, Lashinger ES, Laping NJ, Su X.

Neurourol Urodyn. 2009;28(5):442-6. doi: 10.1002/nau.20650.

PMID:
19030181
16.

Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.

Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD, McDonnell DP.

Cancer Res. 2008 Sep 15;68(18):7475-83. doi: 10.1158/0008-5472.CAN-08-1047.

17.

Modulation of bladder function by prostaglandin EP3 receptors in the central nervous system.

Su X, Leon LA, Wu CW, Morrow DM, Jaworski JP, Hieble JP, Lashinger ES, Jin J, Edwards RM, Laping NJ.

Am J Physiol Renal Physiol. 2008 Oct;295(4):F984-94. doi: 10.1152/ajprenal.90373.2008. Epub 2008 Jul 16.

18.

AMTB, a TRPM8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome.

Lashinger ES, Steiginga MS, Hieble JP, Leon LA, Gardner SD, Nagilla R, Davenport EA, Hoffman BE, Laping NJ, Su X.

Am J Physiol Renal Physiol. 2008 Sep;295(3):F803-10. doi: 10.1152/ajprenal.90269.2008. Epub 2008 Jun 18.

19.

An excitatory role for peripheral EP3 receptors in bladder afferent function.

Su X, Lashinger ES, Leon LA, Hoffman BE, Hieble JP, Gardner SD, Fries HE, Edwards RM, Li J, Laping NJ.

Am J Physiol Renal Physiol. 2008 Aug;295(2):F585-94. doi: 10.1152/ajprenal.90273.2008. Epub 2008 Jun 18.

20.

Enhanced bladder capacity and reduced prostaglandin E2-mediated bladder hyperactivity in EP3 receptor knockout mice.

McCafferty GP, Misajet BA, Laping NJ, Edwards RM, Thorneloe KS.

Am J Physiol Renal Physiol. 2008 Aug;295(2):F507-14. doi: 10.1152/ajprenal.00054.2008. Epub 2008 May 28.

21.

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I.

Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon E, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping NJ, Westfall TD.

J Pharmacol Exp Ther. 2008 Aug;326(2):432-42. doi: 10.1124/jpet.108.139295. Epub 2008 May 22. Erratum in: J Pharmacol Exp Ther. 2011 Jul;338(1):410.

PMID:
18499743
22.

Role of spinal Cav2.2 and Cav2.1 ion channels in bladder nociception.

Su X, Leon LA, Laping NJ.

J Urol. 2008 Jun;179(6):2464-9. doi: 10.1016/j.juro.2008.01.088. Epub 2008 Apr 23.

PMID:
18433788
23.

Effects of the beta 3-adrenergic receptor agonist disodium 5-[(2R)-2-[[(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]propyl]-1,3-benzodioxole-2,2-dicarboxylate (CL-316243) on bladder micturition reflex in spontaneously hypertensive rats.

Leon LA, Hoffman BE, Gardner SD, Laping NJ, Evans C, Lashinger ES, Su X.

J Pharmacol Exp Ther. 2008 Jul;326(1):178-85. doi: 10.1124/jpet.108.138651. Epub 2008 Apr 15.

PMID:
18413856
24.

Oral administration of GW788388, an inhibitor of TGF-beta type I and II receptor kinases, decreases renal fibrosis.

Petersen M, Thorikay M, Deckers M, van Dinther M, Grygielko ET, Gellibert F, de Gouville AC, Huet S, ten Dijke P, Laping NJ.

Kidney Int. 2008 Mar;73(6):705-15. Epub 2007 Dec 12.

25.

Interference with TGF-beta signaling by Smad3-knockout in mice limits diabetic glomerulosclerosis without affecting albuminuria.

Wang A, Ziyadeh FN, Lee EY, Pyagay PE, Sung SH, Sheardown SA, Laping NJ, Chen S.

Am J Physiol Renal Physiol. 2007 Nov;293(5):F1657-65. Epub 2007 Sep 5.

26.

Pharmacologic evaluation of pressor and visceromotor reflex responses to bladder distension.

Su X, Riedel ES, Leon LA, Laping NJ.

Neurourol Urodyn. 2008;27(3):249-53.

PMID:
17598175
27.

Tumor-specific efficacy of transforming growth factor-beta RI inhibition in Eker rats.

Laping NJ, Everitt JI, Frazier KS, Burgert M, Portis MJ, Cadacio C, Gold LI, Walker CL.

Clin Cancer Res. 2007 May 15;13(10):3087-99.

28.

A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.

Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, Short SA, Thompson SK, Stewart EL, Laping NJ, Williams SP, Bray JD.

Mol Endocrinol. 2007 May;21(5):1066-81. Epub 2007 Mar 13.

PMID:
17356170
29.

Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.

Gellibert F, de Gouville AC, Woolven J, Mathews N, Nguyen VL, Bertho-Ruault C, Patikis A, Grygielko ET, Laping NJ, Huet S.

J Med Chem. 2006 Apr 6;49(7):2210-21.

PMID:
16570917
30.
31.

Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.

Grygielko ET, Martin WM, Tweed C, Thornton P, Harling J, Brooks DP, Laping NJ.

J Pharmacol Exp Ther. 2005 Jun;313(3):943-51. Epub 2005 Mar 15.

PMID:
15769863
32.

SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility.

Hjelmeland MD, Hjelmeland AB, Sathornsumetee S, Reese ED, Herbstreith MH, Laping NJ, Friedman HS, Bigner DD, Wang XF, Rich JN.

Mol Cancer Ther. 2004 Jun;3(6):737-45.

33.

SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.

DaCosta Byfield S, Major C, Laping NJ, Roberts AB.

Mol Pharmacol. 2004 Mar;65(3):744-52.

PMID:
14978253
34.

Tgf-beta3-induced palatal fusion is mediated by Alk-5/Smad pathway.

Dudas M, Nagy A, Laping NJ, Moustakas A, Kaartinen V.

Dev Biol. 2004 Feb 1;266(1):96-108.

35.

Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system.

Dluzen DE, Tweed C, Anderson LI, Laping NJ.

Neuroendocrinology. 2003 Apr;77(4):232-8.

PMID:
12766323
36.

ALK5 inhibition in renal disease.

Laping NJ.

Curr Opin Pharmacol. 2003 Apr;3(2):204-8. Review.

PMID:
12681245
37.

Effects of angiotensins II and IV on blood pressure, renal function, and PAI-1 expression in the heart and kidney of the rat.

Abrahamsen CT, Pullen MA, Schnackenberg CG, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

Pharmacology. 2002 Sep;66(1):26-30.

PMID:
12169762
38.

SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Inman GJ, Nicolás FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS.

Mol Pharmacol. 2002 Jul;62(1):65-74.

PMID:
12065756
39.

Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.

Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA.

Mol Pharmacol. 2002 Jul;62(1):58-64.

PMID:
12065755
40.

The angiotensin type 1 receptor antagonist, eprosartan, attenuates the progression of renal disease in spontaneously hypertensive stroke-prone rats with accelerated hypertension.

Abrahamsen CT, Barone FC, Campbell WG Jr, Nelson AH, Contino LC, Pullen MA, Grygielko ET, Edwards RM, Laping NJ, Brooks DP.

J Pharmacol Exp Ther. 2002 Apr;301(1):21-8.

PMID:
11907153
41.

Identification of novel inhibitors of the transforming growth factor beta1 (TGF-beta1) type 1 receptor (ALK5).

Callahan JF, Burgess JL, Fornwald JA, Gaster LM, Harling JD, Harrington FP, Heer J, Kwon C, Lehr R, Mathur A, Olson BA, Weinstock J, Laping NJ.

J Med Chem. 2002 Feb 28;45(5):999-1001.

PMID:
11855979
42.

Role of caspases in human renal proximal tubular epithelial cell apoptosis.

Wong VY, Keller PM, Nuttall ME, Kikly K, DeWolf WE Jr, Lee D, Ali SM, Nadeau DP, Grygielko ET, Laping NJ, Brooks DP.

Eur J Pharmacol. 2001 Dec 21;433(2-3):135-40.

PMID:
11755144
43.

Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression.

Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, Gygielko E, Campbell WG Jr, Barone F, Brooks DP.

Br J Pharmacol. 2001 Nov;134(5):977-84.

44.

The role of transforming growth factor-beta and its receptors in human prostate smooth muscle cell fibronectin production.

Butter S, Laping NJ, Pullen M, Grygielko E, Olson B, Brooks DP.

Eur J Pharmacol. 2001 Jun 22;422(1-3):47-52.

PMID:
11430912
45.
46.

Hepatocyte growth factor in renal disease: cause or cure?

Laping NJ.

Cell Mol Life Sci. 1999 Oct 30;56(5-6):371-7. Review.

PMID:
11212291
47.
48.

Gene expression in rats with renal disease treated with the angiotensin II receptor antagonist, eprosartan.

Wong VY, Laping NJ, Contino LC, Olson BA, Grygielko E, Brooks DP.

Physiol Genomics. 2000 Nov 9;4(1):35-42.

PMID:
11074011
49.

Renal vasopressin receptor expression and function in rats following spaceflight.

Brooks DP, Nambi P, Laping NJ, Olson BA, Pullen M, Wade CE.

J Appl Physiol (1985). 2000 Apr;88(4):1316-20.

50.

Hepatocyte growth factor: a regulator of extracellular matrix genes in mouse mesangial cells.

Laping NJ, Olson BA, Ho T, Ziyadeh FN, Albrightson CR.

Biochem Pharmacol. 2000 Apr 1;59(7):847-53.

PMID:
10718343

Supplemental Content

Loading ...
Support Center